Pascal Soriot
- All
- News
- Videos
-
Top UK CEOs Have Already Earned More Money Than Average Workers Will All Year
These findings have sparked concerns about income inequality and the impact of high CEO pay on the broader economy.
-
AstraZeneca's Pascal Soriot: The Man Behind The Vaccine
Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against Covid-19.
-
Oxford Vaccine Will Protect 95 Per Cent, Says AstraZeneca CEO: Report
The Oxford coronavirus vaccine will "protect 95 per cent of patients" and is "as effective as the Pfizer and Moderna" alternatives, Pascal Soriot, the chief executive of AstraZeneca, told British daily The Sunday Times
-
Lower First Dose Means More People Can Be Vaccinated Faster: AstraZeneca
AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British drugmaker unveiled interim late-stage trial results.
-
Top UK CEOs Have Already Earned More Money Than Average Workers Will All Year
These findings have sparked concerns about income inequality and the impact of high CEO pay on the broader economy.
-
AstraZeneca's Pascal Soriot: The Man Behind The Vaccine
Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against Covid-19.
-
Oxford Vaccine Will Protect 95 Per Cent, Says AstraZeneca CEO: Report
The Oxford coronavirus vaccine will "protect 95 per cent of patients" and is "as effective as the Pfizer and Moderna" alternatives, Pascal Soriot, the chief executive of AstraZeneca, told British daily The Sunday Times
-
Lower First Dose Means More People Can Be Vaccinated Faster: AstraZeneca
AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British drugmaker unveiled interim late-stage trial results.
